Results 141 to 150 of about 88,800 (280)

A Pilot Study of 18F‐rhPSMA‐7.3‐PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease

open access: yesThe Prostate, Volume 86, Issue 8, Page 865-871, June 2026.
ABSTRACT Introduction PSMA‐PET offers an opportunity to reduce the mischaracterization of disease in active surveillance (AS) and focal therapy (FT) candidates. We describe the results of a pilot clinical trial evaluating 18F‐radiohybrid(rh)PSMA‐7.3‐PET/MRI to detect occult adverse pathology among potential AS and FT candidates (NCT05852041).
Ridwan Alam   +11 more
wiley   +1 more source

A Feasibility Study of the Repurposing of Prazosin to Improve Treatment Outcomes in Men Receiving Radiotherapy for Prostate Cancer (MiniRaP‐00)

open access: yesThe Prostate, Volume 86, Issue 8, Page 891-899, June 2026.
ABSTRACT Background Further work is needed to improve treatment outcomes for prostate cancer (PCa), with the repurposing of the α1‐adrenoreceptor antagonists presenting a potential solution. This feasibility clinical trial presents the first prospective data of the use of an α1‐adrenoreceptor antagonist in men undergoing radiotherapy for PCa.
Liam D. King   +8 more
wiley   +1 more source

Harnessing the Power of Data to Improve Prostate Cancer Pathways: The South West Prostate Cancer Dashboard

open access: yesTrends in Urology &Men's Health, Volume 17, Issue 3, June 2026.
ABSTRACT Prostate cancer is now the most frequently diagnosed cancer in UK men. Faster diagnostic pathways form a key component of the NHS Cancer Programme's strategic approach to improving patient outcomes. The Prostate cancer diagnostic pathway involves a number of stages which create potential areas of delay.
Mini Sardar   +7 more
wiley   +1 more source

Approaches to radical prostatectomy

open access: yesJournal of Comparative Effectiveness Research, 2014
Michael, Froehner, Manfred P, Wirth
openaire   +2 more sources

Advances in Erectile Dysfunction Management: What Does Work

open access: yesTrends in Urology &Men's Health, Volume 17, Issue 3, June 2026.
ABSTRACT Erectile dysfunction (ED) is a prevalent and multifactorial disorder that substantially affects quality of life. Pathophysiology includes vascular, neurogenic, drug‐induced, and psychogenic causes, and frequently coexists with cardiometabolic disease.
Jolie Shen   +3 more
wiley   +1 more source

Emerging Treatments for Erectile Dysfunction

open access: yesTrends in Urology &Men's Health, Volume 17, Issue 3, June 2026.
ABSTRACT Erectile dysfunction (ED) is a prevalent condition that can significantly affect men's sexual health and quality of life, and for which there are many well‐studied effective treatments. In spite of this, many individuals still seek out alternative therapies.
Resa Magill   +3 more
wiley   +1 more source

Outcomes After Laparoscopic Radical Prostatectomy Versus da Vinci Robot-Assisted Laparoscopic Radical Prostatectomy. [PDF]

open access: yesCureus
Tejeda-Andrade C   +6 more
europepmc   +1 more source

Medical image computing and computer-aided medical interventions applied to soft tissues. Work in progress in urology

open access: yes, 2006
Until recently, Computer-Aided Medical Interventions (CAMI) and Medical Robotics have focused on rigid and non deformable anatomical structures. Nowadays, special attention is paid to soft tissues, raising complex issues due to their mobility and ...
Bart, Stéphane   +18 more
core   +1 more source

Cytoreductive Radical Prostatectomy in Oligometastatic Prostate Cancer: Single-Centre Experience. [PDF]

open access: yesBJUI Compass
Rouf KA   +7 more
europepmc   +1 more source

Targeted microwave ablation of localised prostate cancer (VIOLETTE trial): a prospective multicentre study

open access: yesBJU International, Volume 137, Issue 6, Page 1032-1039, June 2026.
Objective To assess the oncological outcomes of targeted microwave ablation (TMA) using organ‐based tracking (OBT) Fusion® via KOELIS Trinity® (KOELIS, Meylan, France) in men with intermediate‐risk prostate cancer (PCa): the VIOLETTE trial (ClinicalTrials.gov identifier: NCT04582656) Patients and Method In this prospective phase II, multicentre ...
Nicolas Barry Delongchamps   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy